Search results
Results From The WOW.Com Content Network
PF-05089771 is a selective, small-molecule Na v 1.7 and Na v 1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic. [ 1 ] [ 2 ] [ 3 ] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia .
PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α 2 δ calcium channels (1 and 2).It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and ...
Esreboxetine (developmental code names AXS-14, PNU-165442G) is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued.
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. [1] Tanezumab was discovered and developed by Rinat Neuroscience [ 2 ] and was acquired by Pfizer in 2006.
In September 2024, Pfizer disclosed that ponsegromab led to significant body weight increases in patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer in a phase 2 clinical trial.
The U.S. Food and Drug Administration has approved Pfizer's newest drug on the migraine market, Zavzpret (zavegepant) -- the first and only migraine treatment of its kind to be offered in nasal spray.
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.
PZM21 is an experimental opioid analgesic drug that is being researched for the treatment of pain. [1] It is claimed to be a functionally selective μ-opioid receptor agonist which produces μ-opioid receptor mediated G protein signaling, with potency and efficacy similar to morphine, but with less β-arrestin 2 recruitment. [2]